The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

Review Article Published: 20 July 2020 The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies Tobias Bald, Matthew F. Krummel, Mark J. Smyth & Kevin C. Barry Nature Immunology volume 21, pages835–847(2020)Cite this article 5402 Accesses 67 Altmetric Metricsdetails Abstract Natural killer (NK) cells belong to the innate immune system and contribute to protecting the host through killing of infected, foreign, stressed or transformed cells. Additionally, via cellular cross-talk, NK cells orchestrate antitumor immune responses. Hence, significant efforts have been undertaken to exploit the therapeutic properties of NK cells in cancer. Current strategies in preclinical and clinical development include adoptive transfer therapies, direct stimulation, recruitment of NK cells into the tumor microenvironment (TME), blockade of inhibitory receptors that limit NK cell functions, and therapeutic modulation of the TME to enhance antitumor NK cell function. In this Review, we introduce the NK cell–cancer cycle to highlight recent advances in NK cell biology and to discuss the progress and problems of NK cell–based cancer immunotherapies